Previous 10 | Next 10 |
The European Commission (EC) approved PTC Therapeutics' ( NASDAQ: PTCT ) one-time gene replacement therapy Upstaza to treat aromatic L-amino acid decarboxylase (AADC) deficiency in children and adults. The company said Upstaza (eladocagene exuparvovec) i...
SOLANA BEACH, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain today congratulates partner Neurona Therapeutics on dosing the first patie...
SOLANA BEACH, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced the receipt of certification for the Medical Device Single ...
The following slide deck was published by ClearPoint Neuro, Inc. in conjunction with this event. For further details see: Clearpoint Neuro (CLPT) Investor presentations - Slideshow
Covid remains a short-term headwind for ClearPoint Neuro's Functional Neuro Navigation segment. There are 45 biopharma partners versus 40 in the previous quarter. PTC-AADC is to commercialize later in the year. Operating losses have declined, and operational efficiency has improve...
Gainers: Immix Biopharma (IMMX) +48%. MDxHealth (MDXH) +31%. ClearPoint Neuro (CLPT) +16%. Covetrus (CVET) +14%. Kronos Bio (KRON) +13%. Losers: Evofem Biosciences (EVFM) -58%. Bright Green (BGXX) -26%. Foghorn Therapeutics (FHTX) -19%. N...
SOLANA BEACH, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates partner PTC Therapeutics for receiving a positive opinio...
SOLANA BEACH, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it will present investigational research and exhibit at the ...
The following slide deck was published by ClearPoint Neuro, Inc. in conjunction with this event. For further details see: ClearPoint Neuro (CLPT) Investor Presentation - Slideshow
ClearPoint Neuro's (NASDAQ:CLPT) stock rose ~18% after the company's Q1 results beat analysts' estimates and it raised lower-end of its FY22 revenue outlook a day ago. Net loss narrowed to -$3.96M, compared to -$2.54M in Q1 2021. GAAP EPS of -$0.17, beat estimates by $0.03. Total revenue...
News, Short Squeeze, Breakout and More Instantly...
ClearPoint Neuro, Inc. Company Name:
CLPT Stock Symbol:
NASDAQ Market:
ClearPoint Neuro, Inc. Website:
SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its ...
2024-07-15 17:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...